(1R,2S,8R,11S,12S)-12-methyl-6-thiapentacyclo[9.8.0.02,8.05,8.012,17]nonadecan-7-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1R,2S,8R,11S,12S)-12-methyl-6-thiapentacyclo[9.8.0.02,8.05,8.012,17]nonadecan-7-ol
• 化学式: C₁₉H₃₀OS
• 分子量: 306.5
• InChiKey: RNQCFFVLSOSAQF-JHJRCGRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY
  申请人：Shanghai Dude Medical Technology Co., Ltd

  公开号：EP3643716A1

  公开（公告）日：2020-04-29

  The present invention provides a class of novel compounds having Btk selective inhibitory activity, better metabolic stability and the like.

  本发明提供了一类具有 Btk 选择性抑制活性、更好的代谢稳定性等特点的新型化合物。
• A METHOD FOR TREATING TUMOR BY USING RECOMBINANT INTERFERON WITH CHANGED SPATIAL CONFIGURATION
  申请人：Superlab Far East Limited

  公开号：EP2941264A2

  公开（公告）日：2015-11-11
• RECOMBINANT INTERFERON WITH CHANGED SPATIAL CONFIGURATION FOR USE IN THE TREATMENT OF MALIGNANT PLEURAL EFFUSION, MALIGNANT ASCITES, AND/OR MALIGNANT PERICARDIAL EFFUSION
  申请人：Superlab Far East Limited

  公开号：EP2941264B1

  公开（公告）日：2021-03-10
• EP3753952A1
  申请人：——

  公开号：EP3753952A1

  公开（公告）日：2020-12-23
• METHOD FOR TREATING TUMOR BY USING RECOMBINANT INTERFERON WITH CHANGED SPATIAL CONFIGURATION
  申请人：SUPERLAB FAR EAST LIMITED

  公开号：US20180326012A1

  公开（公告）日：2018-11-15

  The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.